The targeted delivery of IL17 to the mouse tumor neo-vasculature enhances angiogenesis but does not reduce tumor growth rate
There has been a long controversy as to whether interleukin-17 (IL17) has an impact on tumor growth. In order to assess whether IL17 may affect tumor growth, it would be convenient to achieve high levels of this pro-inflammatory cytokine at the tumor neo-vasculature, since IL17 is known to promote a...
Gespeichert in:
| Veröffentlicht in: | Angiogenesis (London) 2012-03, Vol.15 (1), p.165-169 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 169 |
|---|---|
| container_issue | 1 |
| container_start_page | 165 |
| container_title | Angiogenesis (London) |
| container_volume | 15 |
| creator | Pasche, Nadine Frey, Katharina Neri, Dario |
| description | There has been a long controversy as to whether interleukin-17 (IL17) has an impact on tumor growth. In order to assess whether IL17 may affect tumor growth, it would be convenient to achieve high levels of this pro-inflammatory cytokine at the tumor neo-vasculature, since IL17 is known to promote angiogenesis. Here, we have generated and tested in vivo a fusion protein, consisting of the F8 antibody (specific to the alternatively spliced EDA domain of fibronectin, a marker of angiogenesis) and of murine IL17 (mIL17). The resulting immunocytokine (termed F8-mIL17) was shown to selectively localize at the tumor neo-vasculature and to vigorously promote tumor angiogenesis, without however reducing or enhancing tumor growth rate both in immunocompetent and in immunodeficient mice. |
| doi_str_mv | 10.1007/s10456-011-9239-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_920784862</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2580638821</sourcerecordid><originalsourceid>FETCH-LOGICAL-c443t-cf602a4b803b68f58440cde77bf1029f7283068b28ea63312320f2bf50c7edfc3</originalsourceid><addsrcrecordid>eNp1kUtr3DAUhUVpaaZJf0A3RRRCVm6uJFuSlyU0aWCgm3RtZPnK42BbqR4pgf74aphJA4WuBFffOfdxCPnA4DMDUJeRQd3IChirWi7aSr8iG9YoUSkO7WuygVa2lWwVnJB3Md4DlIKu35ITzqHhrG025PfdDmkyYcSEAx1wnh4xPFHv6O2WKZo8TQVYfI4Fy4sPdEVfPZpo82xSDkhx3ZnVYqRmHSc_4opxirTPiQ6-VFefaMAh22f9GPyvtKPBJDwjb5yZI74_vqfkx_XXu6tv1fb7ze3Vl21l61qkyjoJ3NS9BtFL7Rpd12AHVKp3DHjrFNcCpO65RiOFYFxwcLx3DViFg7PilFwcfB-C_5kxpm6ZosV5NmWZHLuWg9K1lryQn_4h730OaxluD3FRF-sCsQNkg48xoOsewrSY8NQx6PbBdIdguhJMtw-m00Xz8Wic-wWHv4rnJApwfgTKbc3sQjnqFF-4plFSCVY4fuBi-VpHDC8T_r_7H8RCpfQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>920234320</pqid></control><display><type>article</type><title>The targeted delivery of IL17 to the mouse tumor neo-vasculature enhances angiogenesis but does not reduce tumor growth rate</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Pasche, Nadine ; Frey, Katharina ; Neri, Dario</creator><creatorcontrib>Pasche, Nadine ; Frey, Katharina ; Neri, Dario</creatorcontrib><description>There has been a long controversy as to whether interleukin-17 (IL17) has an impact on tumor growth. In order to assess whether IL17 may affect tumor growth, it would be convenient to achieve high levels of this pro-inflammatory cytokine at the tumor neo-vasculature, since IL17 is known to promote angiogenesis. Here, we have generated and tested in vivo a fusion protein, consisting of the F8 antibody (specific to the alternatively spliced EDA domain of fibronectin, a marker of angiogenesis) and of murine IL17 (mIL17). The resulting immunocytokine (termed F8-mIL17) was shown to selectively localize at the tumor neo-vasculature and to vigorously promote tumor angiogenesis, without however reducing or enhancing tumor growth rate both in immunocompetent and in immunodeficient mice.</description><identifier>ISSN: 0969-6970</identifier><identifier>EISSN: 1573-7209</identifier><identifier>DOI: 10.1007/s10456-011-9239-8</identifier><identifier>PMID: 22052195</identifier><identifier>CODEN: AGIOFT</identifier><language>eng</language><publisher>Dordrecht: Springer Netherlands</publisher><subject>Animals ; Antibodies - immunology ; Biological and medical sciences ; Biomedical and Life Sciences ; Biomedicine ; Blood and lymphatic vessels ; Blood vessels and receptors ; Brief Communication ; Cancer Research ; Cardiology ; Cardiology. Vascular system ; Cell Biology ; Cell Line ; Cell Proliferation - drug effects ; Cloning, Molecular ; Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous ; Drug Delivery Systems - methods ; Fundamental and applied biological sciences. Psychology ; Interleukin-17 - pharmacology ; Interleukin-17 - therapeutic use ; Medical sciences ; Mice ; Neoplasms - blood supply ; Neoplasms - drug therapy ; Neoplasms - pathology ; Neovascularization, Pathologic - drug therapy ; Neovascularization, Pathologic - pathology ; Oncology ; Ophthalmology ; Recombinant Fusion Proteins - pharmacology ; Recombinant Fusion Proteins - therapeutic use ; Subcutaneous Tissue - drug effects ; Subcutaneous Tissue - pathology ; Vertebrates: cardiovascular system</subject><ispartof>Angiogenesis (London), 2012-03, Vol.15 (1), p.165-169</ispartof><rights>Springer Science+Business Media B.V. 2011</rights><rights>2015 INIST-CNRS</rights><rights>Springer Science+Business Media B.V. 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c443t-cf602a4b803b68f58440cde77bf1029f7283068b28ea63312320f2bf50c7edfc3</citedby><cites>FETCH-LOGICAL-c443t-cf602a4b803b68f58440cde77bf1029f7283068b28ea63312320f2bf50c7edfc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10456-011-9239-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10456-011-9239-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25576731$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22052195$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pasche, Nadine</creatorcontrib><creatorcontrib>Frey, Katharina</creatorcontrib><creatorcontrib>Neri, Dario</creatorcontrib><title>The targeted delivery of IL17 to the mouse tumor neo-vasculature enhances angiogenesis but does not reduce tumor growth rate</title><title>Angiogenesis (London)</title><addtitle>Angiogenesis</addtitle><addtitle>Angiogenesis</addtitle><description>There has been a long controversy as to whether interleukin-17 (IL17) has an impact on tumor growth. In order to assess whether IL17 may affect tumor growth, it would be convenient to achieve high levels of this pro-inflammatory cytokine at the tumor neo-vasculature, since IL17 is known to promote angiogenesis. Here, we have generated and tested in vivo a fusion protein, consisting of the F8 antibody (specific to the alternatively spliced EDA domain of fibronectin, a marker of angiogenesis) and of murine IL17 (mIL17). The resulting immunocytokine (termed F8-mIL17) was shown to selectively localize at the tumor neo-vasculature and to vigorously promote tumor angiogenesis, without however reducing or enhancing tumor growth rate both in immunocompetent and in immunodeficient mice.</description><subject>Animals</subject><subject>Antibodies - immunology</subject><subject>Biological and medical sciences</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Blood and lymphatic vessels</subject><subject>Blood vessels and receptors</subject><subject>Brief Communication</subject><subject>Cancer Research</subject><subject>Cardiology</subject><subject>Cardiology. Vascular system</subject><subject>Cell Biology</subject><subject>Cell Line</subject><subject>Cell Proliferation - drug effects</subject><subject>Cloning, Molecular</subject><subject>Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous</subject><subject>Drug Delivery Systems - methods</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Interleukin-17 - pharmacology</subject><subject>Interleukin-17 - therapeutic use</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Neoplasms - blood supply</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - pathology</subject><subject>Neovascularization, Pathologic - drug therapy</subject><subject>Neovascularization, Pathologic - pathology</subject><subject>Oncology</subject><subject>Ophthalmology</subject><subject>Recombinant Fusion Proteins - pharmacology</subject><subject>Recombinant Fusion Proteins - therapeutic use</subject><subject>Subcutaneous Tissue - drug effects</subject><subject>Subcutaneous Tissue - pathology</subject><subject>Vertebrates: cardiovascular system</subject><issn>0969-6970</issn><issn>1573-7209</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kUtr3DAUhUVpaaZJf0A3RRRCVm6uJFuSlyU0aWCgm3RtZPnK42BbqR4pgf74aphJA4WuBFffOfdxCPnA4DMDUJeRQd3IChirWi7aSr8iG9YoUSkO7WuygVa2lWwVnJB3Md4DlIKu35ITzqHhrG025PfdDmkyYcSEAx1wnh4xPFHv6O2WKZo8TQVYfI4Fy4sPdEVfPZpo82xSDkhx3ZnVYqRmHSc_4opxirTPiQ6-VFefaMAh22f9GPyvtKPBJDwjb5yZI74_vqfkx_XXu6tv1fb7ze3Vl21l61qkyjoJ3NS9BtFL7Rpd12AHVKp3DHjrFNcCpO65RiOFYFxwcLx3DViFg7PilFwcfB-C_5kxpm6ZosV5NmWZHLuWg9K1lryQn_4h730OaxluD3FRF-sCsQNkg48xoOsewrSY8NQx6PbBdIdguhJMtw-m00Xz8Wic-wWHv4rnJApwfgTKbc3sQjnqFF-4plFSCVY4fuBi-VpHDC8T_r_7H8RCpfQ</recordid><startdate>20120301</startdate><enddate>20120301</enddate><creator>Pasche, Nadine</creator><creator>Frey, Katharina</creator><creator>Neri, Dario</creator><general>Springer Netherlands</general><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20120301</creationdate><title>The targeted delivery of IL17 to the mouse tumor neo-vasculature enhances angiogenesis but does not reduce tumor growth rate</title><author>Pasche, Nadine ; Frey, Katharina ; Neri, Dario</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c443t-cf602a4b803b68f58440cde77bf1029f7283068b28ea63312320f2bf50c7edfc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Animals</topic><topic>Antibodies - immunology</topic><topic>Biological and medical sciences</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Blood and lymphatic vessels</topic><topic>Blood vessels and receptors</topic><topic>Brief Communication</topic><topic>Cancer Research</topic><topic>Cardiology</topic><topic>Cardiology. Vascular system</topic><topic>Cell Biology</topic><topic>Cell Line</topic><topic>Cell Proliferation - drug effects</topic><topic>Cloning, Molecular</topic><topic>Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous</topic><topic>Drug Delivery Systems - methods</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Interleukin-17 - pharmacology</topic><topic>Interleukin-17 - therapeutic use</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Neoplasms - blood supply</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - pathology</topic><topic>Neovascularization, Pathologic - drug therapy</topic><topic>Neovascularization, Pathologic - pathology</topic><topic>Oncology</topic><topic>Ophthalmology</topic><topic>Recombinant Fusion Proteins - pharmacology</topic><topic>Recombinant Fusion Proteins - therapeutic use</topic><topic>Subcutaneous Tissue - drug effects</topic><topic>Subcutaneous Tissue - pathology</topic><topic>Vertebrates: cardiovascular system</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pasche, Nadine</creatorcontrib><creatorcontrib>Frey, Katharina</creatorcontrib><creatorcontrib>Neri, Dario</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Angiogenesis (London)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pasche, Nadine</au><au>Frey, Katharina</au><au>Neri, Dario</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The targeted delivery of IL17 to the mouse tumor neo-vasculature enhances angiogenesis but does not reduce tumor growth rate</atitle><jtitle>Angiogenesis (London)</jtitle><stitle>Angiogenesis</stitle><addtitle>Angiogenesis</addtitle><date>2012-03-01</date><risdate>2012</risdate><volume>15</volume><issue>1</issue><spage>165</spage><epage>169</epage><pages>165-169</pages><issn>0969-6970</issn><eissn>1573-7209</eissn><coden>AGIOFT</coden><abstract>There has been a long controversy as to whether interleukin-17 (IL17) has an impact on tumor growth. In order to assess whether IL17 may affect tumor growth, it would be convenient to achieve high levels of this pro-inflammatory cytokine at the tumor neo-vasculature, since IL17 is known to promote angiogenesis. Here, we have generated and tested in vivo a fusion protein, consisting of the F8 antibody (specific to the alternatively spliced EDA domain of fibronectin, a marker of angiogenesis) and of murine IL17 (mIL17). The resulting immunocytokine (termed F8-mIL17) was shown to selectively localize at the tumor neo-vasculature and to vigorously promote tumor angiogenesis, without however reducing or enhancing tumor growth rate both in immunocompetent and in immunodeficient mice.</abstract><cop>Dordrecht</cop><pub>Springer Netherlands</pub><pmid>22052195</pmid><doi>10.1007/s10456-011-9239-8</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0969-6970 |
| ispartof | Angiogenesis (London), 2012-03, Vol.15 (1), p.165-169 |
| issn | 0969-6970 1573-7209 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_920784862 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Animals Antibodies - immunology Biological and medical sciences Biomedical and Life Sciences Biomedicine Blood and lymphatic vessels Blood vessels and receptors Brief Communication Cancer Research Cardiology Cardiology. Vascular system Cell Biology Cell Line Cell Proliferation - drug effects Cloning, Molecular Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous Drug Delivery Systems - methods Fundamental and applied biological sciences. Psychology Interleukin-17 - pharmacology Interleukin-17 - therapeutic use Medical sciences Mice Neoplasms - blood supply Neoplasms - drug therapy Neoplasms - pathology Neovascularization, Pathologic - drug therapy Neovascularization, Pathologic - pathology Oncology Ophthalmology Recombinant Fusion Proteins - pharmacology Recombinant Fusion Proteins - therapeutic use Subcutaneous Tissue - drug effects Subcutaneous Tissue - pathology Vertebrates: cardiovascular system |
| title | The targeted delivery of IL17 to the mouse tumor neo-vasculature enhances angiogenesis but does not reduce tumor growth rate |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T15%3A41%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20targeted%20delivery%20of%20IL17%20to%20the%20mouse%20tumor%20neo-vasculature%20enhances%20angiogenesis%20but%20does%20not%20reduce%20tumor%20growth%20rate&rft.jtitle=Angiogenesis%20(London)&rft.au=Pasche,%20Nadine&rft.date=2012-03-01&rft.volume=15&rft.issue=1&rft.spage=165&rft.epage=169&rft.pages=165-169&rft.issn=0969-6970&rft.eissn=1573-7209&rft.coden=AGIOFT&rft_id=info:doi/10.1007/s10456-011-9239-8&rft_dat=%3Cproquest_cross%3E2580638821%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=920234320&rft_id=info:pmid/22052195&rfr_iscdi=true |